newsfilter
← Latest News
GlobeNewswire·

AlphaTON's Cyncado Therapeutics and Australia's ADDRI to Launch Investigator-Initiated Mesothelioma Clinical Trial of TT-4, Complementing U.S. Plans

ATON
  • AlphaTON Capital Corp (NASDAQ: ATON) and its subsidiary Cyncado Therapeutics announced a non-binding Letter of Intent with Australia's ADDRI to conduct an investigator-initiated clinical trial.
  • The trial will evaluate Cyncado's selective A2B receptor antagonist TT-4 in mesothelioma patients within Australia.
  • The Australian study plans to enroll approximately 50 patients & will run alongside Cyncado's U.S. mesothelioma activities subject to a definitive agreement & approvals.
  • The trial addresses the urgent need for effective second-line treatments where no standard exists & outcomes remain poor following first-line therapy.
  • The program is led by A/Prof Steven Kao of Chris O'Brien Lifehouse/ADDRI & Dr Melvin Chin of Sir Charles Gairdner Hospital/NCARD.
  • Cyncado will provide TT-4 & limited support under a future definitive agreement based on previously shared preclinical findings.
  • Mesothelioma is an aggressive asbestos-linked cancer with high per-capita burden in Australia & no established second-line standard despite first-line improvements.
  • ADDRI serves as the WHO Collaborating Centre for the Elimination of Asbestos-Related Diseases & aims to generate high-quality data to inform global care.
  • Cyncado Therapeutics is developing oral A2B receptor antagonist TT-4 with first-patient dosing targeted for Q1 2026.
  • AlphaTON Capital Corp is a digital asset treasury company managing TON tokens & also advancing therapeutic development through its legacy business.
  • The press release includes forward-looking statements regarding trial implementation, clinical outcomes, & TON ecosystem growth subject to various risks.